A Roadmap to Safe, Efficient, and Stable Lentivirus-Mediated Gene Therapy with Hematopoietic Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 13, Issue 12, 2007, Pages 1407-1416

  Neschadim, Anton ^a,b   McCart, J Andrea ^b,c   Keating, Armand ^a,b,c   Medin, Jeffrey A ^a,b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Bone marrow; Gene therapy; Hematopoietic stem cell; Lentivirus; Oncoretrovirus; Transplantation

Indexed keywords

ACICLOVIR; ADENOSINE DEAMINASE; BETA GLOBIN; BETA GLUCURONIDASE; GANCICLOVIR; HERPES SIMPLEX VIRUS THYMIDINE KINASE; INTERLEUKIN 2 RECEPTOR GAMMA; LENTIVIRUS VECTOR; PRODRUG; PROTEIN P47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; RETROVIRUS VECTOR; THYMIDINE KINASE; UNCLASSIFIED DRUG; ZIDOVUDINE;

AUTOIMMUNITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BETA THALASSEMIA; CHRONIC GRANULOMATOUS DISEASE; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DRUG DESIGN; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION PROFILING; GENE INACTIVATION; GENE THERAPY; GRAFT VERSUS HOST REACTION; HUMAN; MOLONEY LEUKEMIA ONCOVIRUS; MYELOPROLIFERATIVE DISORDER; NONHUMAN; REVIEW; SARCOMA VIRUS; SIGNAL TRANSDUCTION; SPLEEN FOCUS FORMING VIRUS; SUICIDE GENE; T CELL LYMPHOMA; TARGET CELL; TERATOMA; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LENTIVIRUS; RECOMBINANT PROTEINS; SEVERE COMBINED IMMUNODEFICIENCY; TARGETED GENE REPAIR; TRANSPLANTATION, AUTOLOGOUS;

EID: 36049014397     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2007.09.014     Document Type: Review

References (104)

1. Gennero L., Mortimer P., Sperber K., et al. Stem cells: an alternative to organ transplantation in chronic, degenerative and infectious diseases?. New Microbiol 29 (2006) 151-167
2. Petersdorf E.W., Gooley T., Malkki M., et al. Clinical significance of donor-recipient HLA matching on survival after myeloablative hematopoietic cell transplantation from unrelated donors. Tissue Antigens 69 Suppl 1 (2007) 25-30
3. Wingard J.R., Vogelsang G.B., and Deeg H.J. Stem cell transplantation: supportive care and long-term complications. Hematology Am Soc Hematol Educ Program (2002) 422-444
4. Cao T.M., Lo B., Ranheim E.A., et al. Variable hematopoietic graft rejection and graft-versus-host disease in MHC-matched strains of mice. Proc Natl Acad Sci U S A 100 (2003) 11571-11576
5. Scheffold C., Scheffold Y.C., Cao T.M., et al. Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells. Biol Blood Marrow Transplant 11 (2005) 1-12
6. Siatskas C., and Medin J.A. Gene therapy for Fabry disease. J Inherit Metab Dis 24 Suppl 2 (2001) 25-41
7. Markowitz D., Goff S., and Bank A. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 62 (1988) 1120-1124
8. Miyoshi H., Blomer U., Takahashi M., et al. Development of a self-inactivating lentivirus vector. J Virol 72 (1998) 8150-8157
9. Sambrook J., Westphal H., Srinivasan P.R., et al. The integrated state of viral DNA in SV40-transformed cells. Proc Natl Acad Sci U S A 60 (1968) 1288-1295
10. Rogers S., and Pfuderer P. Use of viruses as carriers of added genetic information. Nature 219 (1968) 749-751
11. Cohen S.N., Chang A.C., Boyer H.W., et al. Construction of biologically functional bacterial plasmids in vitro. Proc Natl Acad Sci U S A 70 (1973) 3240-3244
12. Wei C.M., Gibson M., Spear P.G., et al. Construction and isolation of a transmissible retrovirus containing the src gene of Harvey murine sarcoma virus and the thymidine kinase gene of herpes simplex virus type 1. J Virol 39 (1981) 935-944
13. Temin H.M. Structure, variation and synthesis of retrovirus long-terminal repeat. Cell 27 1 Pt 2 (1981) 1-3
14. Doehmer J., Barinaga M., Vale W., et al. Introduction of rat growth hormone gene into mouse fibroblasts via a retroviral DNA vector: expression and regulation. Proc Natl Acad Sci U S A 79 (1982) 2268-2272
15. Mann R., Mulligan R.C., and Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33 (1983) 153-159
16. Miller A.D., Law M.F., and Verma I.M. Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene. Mol Cell Biol 5 (1985) 431-437
17. Miller A.D., and Buttimore C. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol Cell Biol 6 (1986) 2895-2902
18. Willis R.C., Jolly D.J., Miller A.D., et al. Partial phenotypic correction of human Lesch-Nyhan (hypoxanthine-guanine phosphoribosyltransferase-deficient) lymphoblasts with a transmissible retroviral vector. J Biol Chem 259 (1984) 7842-7849
19. Williams D.A., Lemischka I.R., Nathan D.G., et al. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature 310 (1984) 476-480
20. Gruber H.E., Finley K.D., Hershberg R.M., et al. Retroviral vector-mediated gene transfer into human hematopoietic progenitor cells. Science 230 (1985) 1057-1061
21. Anderson W.F., Kantoff P., Eglitis M., et al. Gene transfer and expression in nonhuman primates using retroviral vectors. Cold Spring Harb Symp Quant Biol 51 Pt 2 (1986) 1073-1081
22. Kantoff P.W., Kohn D.B., Mitsuya H., et al. Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer. Proc Natl Acad Sci U S A 83 (1986) 6563-6567
23. Williams D.A., Orkin S.H., and Mulligan R.C. Retrovirus-mediated transfer of human adenosine deaminase gene sequences into cells in culture and into murine hematopoietic cells in vivo. Proc Natl Acad Sci U S A 83 (1986) 2566-2570
24. Selden R.F., Skoskiewicz M.J., Howie K.B., et al. Implantation of genetically engineered fibroblasts into mice: implications for gene therapy. Science 236 (1987) 714-718
25. Rosenberg M.B., Friedmann T., Robertson R.C., et al. Grafting genetically modified cells to the damaged brain: restorative effects of NGF expression. Science 242 (1988) 1575-1578
26. Ferrari G., Rossini S., Giavazzi R., et al. An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science 251 (1991) 1363-1366
27. + selected autologous peripheral blood cells transduced with a human ADA gene. Amendment to clinical research project 90-C-195, January 10, 1992. Hum Gene Ther 4 (1993) 521-527
28. Blaese R.M., Culver K.W., Miller A.D., et al. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science 270 (1995) 475-480
29. Bordignon C., Notarangelo L.D., Nobili N., et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270 (1995) 470-475
30. + cells in ADA-deficient SCID neonates. Nat Med 4 (1998) 775-780
31. Cavazzana-Calvo M., Hacein-Bey S., de Saint Basile G., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288 (2000) 669-672
32. Gaspar H.B., Parsley K.L., Howe S., et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364 (2004) 2181-2187
33. Aiuti A., Slavin S., Aker M., et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296 (2002) 2410-2413
34. Booth C., Hershfield M., Notarangelo L., et al. Management options for adenosine deaminase deficiency. Proceedings of the EBMT satellite workshop (Hamburg, March 2006). Clin Immunol 123 (2007) 139-147
35. Hacein-Bey-Abina S., Von Kalle C., Schmidt M., et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302 (2003) 415-419
36. + infected patients grouped according to CD4 count and viral load. Mol Ther 9 (2004) 902-913
37. Levine B.L., Humeau L.M., Boyer J., et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A 103 (2006) 17372-17377
38. Takeuchi Y., Simpson G., Vile R.G., et al. Retroviral pseudotypes produced by rescue of a Moloney murine leukemia virus vector by C-type, but not D-type, retroviruses. Virology 186 (1992) 792-794
39. Yee J.K., Friedmann T., and Burns J.C. Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol 43 Pt A (1994) 99-112
40. Medina M.F., Kobinger G.P., Rux J., et al. Lentiviral vectors pseudotyped with minimal filovirus envelopes increased gene transfer in murine lung. Mol Ther 8 (2003) 777-789
41. Yu S.F., von Ruden T., Kantoff P.W., et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci U S A 83 (1986) 3194-3198
42. Logan A.C., Haas D.L., Kafri T., et al. Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration. J Virol 78 (2004) 8421-8436
43. Modlich U., Bohne J., Schmidt M., et al. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108 (2006) 2545-2553
44. + cells enhances stem cell proliferation. Cancer Res 66 (2006) 11781-11791
45. Adams J.M., and Cory S. Transgenic models of tumor development. Science 254 (1991) 1161-1167
46. Roe T., Reynolds T.C., Yu G., et al. Integration of murine leukemia virus DNA depends on mitosis. EMBO J 12 (1993) 2099-2108
47. Luskey B.D., Lim B., Apperley J.F., et al. Gene transfer into murine hematopoietic stem cells and bone marrow stromal cells. Ann N Y Acad Sci 612 (1990) 398-406
48. + cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 283 (1999) 682-686
49. Follenzi A., Ailles L.E., Bakovic S., et al. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25 (2000) 217-222
50. Bukovsky A.A., Song J.P., and Naldini L. Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J Virol 73 (1999) 7087-7092
51. Cohen J. Building an HIV-proof immune system. Science 317 (2007) 612-614
52. De Palma M., Montini E., Santoni de Sio F.R., et al. Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. Blood 105 (2005) 2307-2315
53. Montini E., Cesana D., Schmidt M., et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24 (2006) 687-696
54. + hematopoietic cells. Blood 110 (2007) 1770-1778
55. Wang G.P., Ciuffi A., Leipzig J., et al. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res 17 (2007) 1186-1194
56. Baum C., Dullmann J., Li Z., et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101 (2003) 2099-2114
57. + progenitors and enzymatic correction of cells from Gaucher patients, with bicistronic vectors. Proc Natl Acad Sci U S A 92 (1995) 12075-12079
58. + cells and corrects the enzyme deficiency in cells from Gaucher patients. Blood 87 (1996) 1754-1762
59. + cells transduced with retroviral vectors containing an intracytoplasmatically truncated version of the human low-affinity nerve growth factor receptor (deltaLNGFR) gene. Hum Gene Ther 8 (1997) 1815-1824
60. Qin G., Takenaka T., Telsch K., et al. Preselective gene therapy for Fabry disease. Proc Natl Acad Sci U S A 98 (2001) 3428-3433
61. Ciuffi A., Diamond T.L., Hwang Y., et al. Modulating target site selection during human immunodeficiency virus DNA integration in vitro with an engineered tethering factor. Hum Gene Ther 17 (2006) 960-967
62. Lewinski M.K., Yamashita M., Emerman M., et al. Retroviral DNA integration: viral and cellular determinants of target-site selection. PLoS Pathog 2 (2006) e60
63. Ren G., Gao K., Bushman F.D., et al. Single-particle image reconstruction of a tetramer of HIV integrase bound to DNA. J Mol Biol 366 (2007) 286-294
64. Plautz G., Nabel E.G., and Nabel G.J. Selective elimination of recombinant genes in vivo with a suicide retroviral vector. New Biol 3 (1991) 709-715
65. Bordignon C., Bonini C., Verzeletti S., et al. Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum Gene Ther 6 (1995) 813-819
66. Greco E., Fogar P., Basso D., et al. Retrovirus-mediated herpes simplex virus thymidine kinase gene transfer in pancreatic cancer cell lines: an incomplete antitumor effect. Pancreas 25 (2002) e21-e29
67. Berger C., Flowers M.E., Warren E.H., et al. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood 107 (2006) 2294-2302
68. Sato T., Neschadim A., Konrad M., et al. Engineered human tmpk/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol Ther 15 (2007) 962-970
69. Ostermann N., Lavie A., Padiyar S., et al. Potentiating AZT activation: structures of wild-type and mutant human thymidylate kinase suggest reasons for the mutants' improved kinetics with the HIV prodrug metabolite AZTMP. J Mol Biol 304 (2000) 43-53
70. Ramsubir S., Yoshimitsu M., and Medin J.A. Anti-CD25 targeted killing of bicistronically transduced cells: a novel safety mechanism against retroviral genotoxicity. Mol Ther 15 (2007) 1174-1181
71. Raper S.E., Chirmule N., Lee F.S., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase-deficient patient following adenoviral gene transfer. Mol Genet Metab 80 (2003) 148-158
72. Gao G., Lebherz C., Weiner D.J., et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103 (2004) 3300-3302
73. Chenuaud P., Larcher T., Rabinowitz J.E., et al. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 103 (2004) 3303-3304
74. Schwella N., Siegert W., Beyer J., et al. Autografting with blood progenitor cells: predictive value of preapheresis blood cell counts on progenitor cell harvest and correlation of the reinfused cell dose with hematopoietic reconstitution. Ann Hematol 71 (1995) 227-234
75. + cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion 38 (1998) 385-391
76. Clackson T., Yang W., Rozamus L.W., et al. Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A 95 (1998) 10437-10442
77. Jin L., Siritanaratkul N., Emery D.W., et al. Targeted expansion of genetically modified bone marrow cells. Proc Natl Acad Sci U S A 95 (1998) 8093-8097
78. Richard R.E., Wood B., Zeng H., et al. Expansion of genetically modified primary human hemopoietic cells using chemical inducers of dimerization. Blood 95 (2000) 430-436
79. Zhao S., Weinreich M.A., Ihara K., et al. In vivo selection of genetically modified erythroid cells using a jak2-based cell growth switch. Mol Ther 10 (2004) 456-468
80. Siatskas C., Underwood J., Ramezani A., et al. Specific pharmacological dimerization of KDR in lentivirally transduced human hematopoietic cells activates anti-apoptotic and proliferative mechanisms. FASEB J 19 (2005) 1752-1754
81. Yoshimitsu M., Higuchi K., Ramsubir S., et al. Efficient correction of Fabry mice and patient cells mediated by lentiviral transduction of hematopoietic stem/progenitor cells. Gene Ther 14 (2007) 256-265
82. Shin K.J., Wall E.A., Zavzavadjian J.R., et al. A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression. Proc Natl Acad Sci U S A 103 (2006) 13759-13764
83. Pfeifer A., Eigenbrod S., Al-Khadra S., et al. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Invest 116 (2006) 3204-3210
84. Figueiredo C., Horn P.A., Blasczyk R., et al. Regulating MHC expression for cellular therapeutics. Transfusion 47 (2007) 18-27
85. Lees J.G., Lim S.A., Croll T., et al. Transplantation of 3D scaffolds seeded with human embryonic stem cells: biological features of surrogate tissue and teratoma-forming potential. Regen Med 2 (2007) 289-300
86. Fong S.P., Tsang K.S., Chan A.B., et al. Trophism of neural progenitor cells to embryonic stem cells: neural induction and transplantation in a mouse ischemic stroke model. J Neurosci Res 85 (2007) 1851-1862
87. Nussbaum J., Minami E., Laflamme M.A., et al. Transplantation of undifferentiated murine embryonic stem cells in the heart: teratoma formation and immune response. FASEB J 21 (2007) 1345-1357
88. Cao F., Drukker M., Lin S., et al. Molecular imaging of embryonic stem cell misbehavior and suicide gene ablation. Cloning Stem Cells 9 (2007) 107-117
89. Ikawa M., Tanaka N., Kao W.W., et al. Generation of transgenic mice using lentiviral vectors: a novel preclinical assessment of lentiviral vectors for gene therapy. Mol Ther 8 (2003) 666-673
90. Li S., Kimura E., Fall B.M., et al. Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin. Gene Ther 12 (2005) 1099-1108
91. Vigna E., Amendola M., Benedicenti F., et al. Efficient Tet-dependent expression of human factor IX in vivo by a new self-regulating lentiviral vector. Mol Ther 11 (2005) 763-775
92. Di Domenico C., Di Napoli D., Gonzalez Y.R., et al. Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy. Hum Gene Ther 17 (2006) 1112-1121
93. Bank A., Dorazio R., and Leboulch P. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Ann N Y Acad Sci 1054 (2005) 308-316
94. Papapetrou E.P., Ziros P.G., Micheva I.D., et al. Gene transfer into human hematopoietic progenitor cells with an episomal vector carrying an S/MAR element. Gene Ther 13 (2006) 40-51
95. Zhou H.S., Zhao N., Li L., et al. Site-specific transfer of an intact beta-globin gene cluster through a new targeting vector. Biochem Biophys Res Commun 356 (2007) 32-37
96. Malech H.L., Maples P.B., Whiting-Theobald N., et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 94 (1997) 12133-12138
97. Malech H.L., Choi U., and Brenner S. Progress toward effective gene therapy for chronic granulomatous disease. Jpn J Infect Dis 57 (2004) S27-S28
98. Schwarzwaelder K., Howe S.J., Schmidt M., et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 117 (2007) 2241-2249
99. Chinen J., Davis J., De Ravin S.S., et al. Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency. Blood 110 (2007) 67-73
100. Gaspar H.B., Bjorkegren E., Parsley K., et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol Ther 14 (2006) 505-513
101. Ott M.G., Schmidt M., Schwarzwaelder K., et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16, or SETBP1. Nat Med 12 (2006) 401-409
102. European Society of Gene Therapy. One of three successfully treated CGD patients in a Swiss-German gene therapy trial died due to his underlying disease. A position statement from the European Society of Gene Therapy (ESGT). J Gene Med 8 (2006) 1435
103. + hematopoietic progenitor cell-directed lentiviral-mediated gene therapy in a xenotransplantation model of lysosomal storage disease. Mol Ther 9 (2004) 856-865
104. Sadelain M., Boulad F., Galanello R., et al. Therapeutic options for patients with severe beta-thalassemia: the need for globin gene therapy. Hum Gene Ther 18 (2007) 1-9